Kevin Ali, Organon CEO
November 11, 2021 07:23 AM ESTUpdated 08:38 AM
Deals
R&D

Months af­ter a Mer­ck spin­out, Organon con­tin­ues its string of deals with a $954M buy­out pack­age

John Carroll

Editor & Founder

Five months af­ter eject­ing out of the moth­er ship at Mer­ck, the women’s health ex­perts at Organon have racked up an­oth­er deal, this time …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi's BTK in­hibitor again slows MS pro­gres­sion, but liv­er en­zymes con­tin­ue to be tricky

Lex­i­con's pres­i­dent to step down as de­ci­sion date looms; Sarep­ta wel­comes Lil­ly, GSK vet to board

Gilead­'s Kite un­cou­ples from Fo­s­un in Chi­na as Yescar­ta faces cov­er­age ob­sta­cles

Ali­gos’ tri­al for oral MASH treat­ment suc­ceeds, but place­bo group shows odd trend

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times